Results 41 to 50 of about 3,746,725 (298)

Clinician barriers, perceptions, and practices in treating patients with hepatitis C virus and substance use disorder in the United States

Preventive Medicine Reports, 2023
The likelihood of clinicians prescribing direct-acting antiviral (DAA) therapy for patients with chronic hepatitis C virus (HCV) and substance use disorder (SUD) was assessed via a survey emailed throughout the United States to clinicians (physicians and
Haesuk Park, Carolyn Brown, Debbie L. Wilson, Pei-Lin Huang, Pilar Hernández-Con, Patrick Horne, Amie Goodin, Amanda Joseph, Rich Segal, Roniel Cabrera, Robert L. Cook   +10 more
doaj   +1 more source

Sustained Virological Response after 8-Week Treatment of Simeprevir with Peginterferon α-2a plus Ribavirin in a Japanese Female with Hepatitis C Virus Genotype 1b and IL28B Minor Genotype

Case Reports in Gastroenterology, 2015
Direct-acting antivirals with or without peginterferon α (PEG-IFN α) plus ribavirin are now available for the treatment of hepatitis C virus (HCV) infection. Direct-acting antivirals are potent inhibitors of HCV replication, but some of them occasionally
Tatsuo Kanda, Masato Nakamura, Reina Sasaki, Shin Yasui, Shingo Nakamoto, Yuki Haga, Xia Jiang, Shuang Wu, Akinobu Tawada, Makoto Arai, Fumio Imazeki, Osamu Yokosuka   +11 more
doaj   +1 more source

Variable short duration treatment versus standard treatment, with and without adjunctive ribavirin, for chronic hepatitis C: the STOP-HCV-1 non-inferiority, factorial RCT

Efficacy and Mechanism Evaluation, 2021
Background: High cure rates with licensed durations of therapy for chronic hepatitis C virus suggest that many patients are overtreated. New strategies in individuals who find it challenging to adhere to standard treatment courses could significantly ...
Graham S Cooke, Sarah Pett, Leanne McCabe, Christopher Jones, Richard Gilson, Sumita Verma, Stephen D Ryder, Jane D Collier, Stephen T Barclay, Aftab Ala, Sanjay Bhagani, Mark Nelson, Chin Lye Ch’Ng, Benjamin Stone, Martin Wiselka, Daniel Forton, Stuart McPherson, Rachel Halford, Dung Nguyen, David Smith, M Azim Ansari, Helen Ainscough, Emily Dennis, Fleur Hudson, Eleanor J Barnes, Ann Sarah Walker, the STOP-HCV trial team   +26 more
doaj   +1 more source

Worsening of Serum Lipid Profile after Direct Acting Antiviral Treatment [PDF]

, 2018
Host lipid metabolism influences viral replication and lifecycle of hepatitis C virus. Our aim was to evaluate changes in glucose and lipid metabolism of patients with chronic hepatitis C after therapy with direct acting antivirals (DAA)
Elena Grandini, Stefano Gitto, Elisabetta Loggi, Andreone, Pietro, Arrigo F.G. Cicero, Gitto, Stefano, Conti, Fabio, Vitale, Giovanni, Giovanni Vitale, Carmela Cursaro, Scuteri, Alessandra, Borghi, Claudio, Loggi, Elisabetta, Claudio Borghi, Guarneri, Valeria, Giovannini, Marina, Grandini, Elena, Marina Giovannini, Fabio Conti, Valeria Guarneri, Pietro Andreone, Cicero, Arrigo F G, Alessandra Scuteri, Cursaro, Carmela, Gitto, S.   +24 more
core   +1 more source

Efficacy of direct-acting antivirals in patients with hepatitis C virus-associated cryoglobulinemic vasculitis: Results of a long-term follow-up

Научно-практическая ревматология, 2023
Objective – to evaluate the long-term outcomes of HCV eradication with direct-acting antivirals (DAAs) in patients with hepatitis C-associated cryoglobulinemic vasculitis (HCV-CV)Materials and methods.
S. V. Gavrisheva, D. T. Abdurakhmanov, N. M. Bulanov, E. L. Tanashhuk, T. P. Rozina, E. N. Nikulkina, S. Yu. Milovanova, E. A. Nabatchikova, A. L. Filatova, E. E. Starostina, T. N. Krasnova, S. V. Moiseev   +11 more
doaj   +1 more source

Properties of HCV direct-acting antivirals.

, 2015
Properties of HCV direct-acting antivirals.
Susanna Naggie (304827), Stacy M. Horner (178713)   +1 more
core   +1 more source

Reasons for not commencing direct-acting antiviral treatment despite unrestricted access for individuals with HIV and hepatitis C virus: a multinational, prospective cohort study. [PDF]

, 2023
BACKGROUND Individuals with HIV and hepatitis C virus (HCV) who remain untreated with direct-acting antivirals can contribute to HCV transmission and HCV-related mortality.
Salmon, Dominique, Hellard, Margaret, van der Valk, Marc, Martinello, Marianne, Matthews, Gail V, Stewart, Ashleigh, Klein, Marina B, Rauch, Andri, Stoove, Mark, Schinkel, Janke, Wittkop, Linda, Berenguer, Juan, Sacks-Davis, Rachel, Smit, Colette, Boyd, Anders, Isfordink, Cas J, Lacombe, Karine, Doyle, Joseph S, van Santen, Daniela K, Daniela K van Santen, Marianne Martinello, Colette Smit, Karine Lacombe, Joseph S Doyle, Cas J Isfordink, Mark Stoove, Gail V Matthews, Dominique Salmon, Andri Rauch, Linda Wittkop, Marc van der Valk, Ashleigh Stewart, Anders Boyd, Juan Berenguer, Janke Schinkel, Marina B Klein, Margaret Hellard, Rachel Sacks-Davis   +37 more
core   +2 more sources

Direct-Acting Antiviral Therapy Outcomes in Canadian Chronic Hepatitis C Telemedicine Patients

Annals of Hepatology, 2017
Introduction: Many of the 300,000 HCV-infected Canadians live in under-served and remote areas without access to HCV healthcare specialists. Telemedicine (TM) and advances in HCV management can facilitate linkage of these marginalized patients to ...
Curtis L. Cooper, Holly Hatashita, Daniel J. Corsi, Parmvir Parmar, Raymond Corrin, Gary Garber   +5 more
doaj   +1 more source

Mortality associated with the treatment of HCV with direct-acting antivirals [PDF]

Gut, 2017
We read with interest the study by Welzel et al 1 confirming the high efficacy of oral direct-acting antiviral agents (DAAs) for the treatment of chronic HCV infection.2 Results about safety are less clear, since in these patients who have a high risk of hepatic decompensation or death within 12 months, the rate of death was 7.8% during treatment and ...
Anne, Laurain, Laura, Kramer, Philippe, Sultanik, Anaïs, Vallet-Pichard, Philippe, Sogni, Stanislas, Pol   +5 more
openaire   +2 more sources

Cryoglobulinaemic vasculitis in a patient with chronic hepatitis C:favourable outcome due to direct-acting antivirals

, 2020
This case report describes a patient who presented with a debilitating hepatitis C virus-related cryoglobulinaemic vasculitis who was treated with immunosuppression and direct-acting antivirals.
Van Paassen, P., Posthouwer, D., Boderie, M.J.M., Aendekerk, J.P.   +3 more
core   +1 more source